Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Acquires Levitra Rights From Bayer; Vytorin Launch Is Still Priority

Executive Summary

Schering-Plough's acquisition of Bayer's primary care products in the U.S. will not distract the company from the launch of Vytorin, Schering CEO Fred Hassan told investors Sept. 13 at a Bear Stearns conference in New York

You may also be interested in...



Schering Licensing Decisions To Focus On Boosting Sales Efficiency – Hassan

Schering-Plough's licensing efforts will focus on bringing in compounds that will increase the efficiency of the firm's marketing efforts, CEO Fred Hassan suggested during an interview with "The Pink Sheet."

Schering Licensing Decisions To Focus On Boosting Sales Efficiency – Hassan

Schering-Plough's licensing efforts will focus on bringing in compounds that will increase the efficiency of the firm's marketing efforts, CEO Fred Hassan suggested during an interview with "The Pink Sheet."

Schering Looking To Expand Therapeutic Frontiers Beyond Cholesterol

Schering-Plough is positioning itself to branch out from its cholesterol base into other therapeutic areas, CEO Fred Hassan said at the Morgan Stanley CEOs Unplugged investor conference on Jan. 4

Related Content

Topics

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel